Sumitomo Pharma Co Ltd 2011 Annual Report with Sustainability Disclosures
The report presents Dainippon Sumitomo Pharma's financial and sustainability performance for the fiscal year ended March 31, 2011. Key business developments include the U.S. market launch of the global strategic product LATUDA® for schizophrenia, entering a European commercialization partnership with Takeda, and expanding overseas revenue. Financially, consolidated net sales reached ¥379.5 billion. The report also details environmental, health, safety, and corporate social responsibility activities, including disaster recovery support for the Great East Japan Earthquake and progress on the Mid-term Environmental Plan.
Company: Sumitomo Pharma Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2011
Type: Annual Report with Sustainability Disclosures
Pages: 78
Back to company
Sumitomo Pharma Co Ltd
Annual Report
The report presents Dainippon Sumitomo Pharma's financial and sustainability performance for the fiscal year ended March 31, 2011. Key business developments include the U.S. market launch of the global strategic product LATUDA® for schizophrenia, entering a European commercialization partnership with Takeda, and expanding overseas revenue. Financially, consolidated net sales reached ¥379.5 billion. The report also details environmental, health, safety, and corporate social responsibility activities, including disaster recovery support for the Great East Japan Earthquake and progress on the Mid-term Environmental Plan.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2011
Reporting Period
Apr 1, 2010 - Mar 31, 2011
Fiscal Year
2011
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Employees